# Investigation of Immunotherapy-induced Alterations to Cellular Communication Networks in Pancreatic Ductal Adenocarcinoma

> **NIH NIH F31** · JOHNS HOPKINS UNIVERSITY · 2024 · $42,074

## Abstract

PROJECT SUMMARY
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest forms of cancer in the United States. The low mutational
burden in PDAC leads to low infiltration of T cells that could become cytotoxic to cancer cells by administration of immune
checkpoint inhibitors (ICIs). Neoantigen vaccines promote T cell invasion, but do not protect T cells from exhaustion.
Analysis of immunotherapy approaches to clinical treatment of PDAC combining cancer vaccines with ICIs suggests that
efficacious immune response involves alterations in cell-cell communication among tumor-invading immune cells. Murine
models of neoantigen response indicate that simultaneous priming of tumor-specific CD8+ and CD4+ T cells increases
survival through CD4+ T cell-dependent enhancement of anti-tumor CD8+ T cell and myeloid cell functions. I hypothesize
that effective immunotherapy response in PDAC is dependent on altering cellular signaling networks in the tumor
microenvironment to maintain durable cytotoxic effector states and hinder immunosuppressive signals. To test this
hypothesis, I will utilize single-cell RNA sequencing (scRNA-seq) data from a compiled atlas of immunotherapy-naïve
PDAC, primary tumors from a neoadjuvant trial of combination immunotherapy for PDAC, and a murine model of
personalized neoantigen vaccine treatment for PDAC. Experiments posed in Aim 1 will develop statistical methods for the
utilization of the cellular communication inference tool Domino in identifying cellular interactions that differentially occur
between treatment groups in scRNA-seq data from clinical trials of combination immunotherapy in humans. Experiments
posed in Aim 2 will identify the mechanism by which the tumor-specific T cells expanded by the neoantigen vaccine
PancVAX2 attack liver metastases in an orthotopic murine model of PDAC through flow cytometry and inference of cell-
cell communication in scRNA-seq data. Collectively, these experiments will inform mechanistic understanding of how
combination immunotherapies enhance immune responses to PDAC through enhancement of T cell cytotoxicity and
alterations of communication between immune cells. This proposed work will have broad applications improving
immunotherapy approaches to the treatment of PDAC and develop computational tools for scRNA-seq analysis to assess
how cellular communication is altered by outside perturbations and sample features.

## Key facts

- **NIH application ID:** 10898376
- **Project number:** 1F31CA284525-01A1
- **Recipient organization:** JOHNS HOPKINS UNIVERSITY
- **Principal Investigator:** Jacob Thomas Mitchell
- **Activity code:** F31 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $42,074
- **Award type:** 1
- **Project period:** 2024-06-03 → 2025-03-04

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10898376

## Citation

> US National Institutes of Health, RePORTER application 10898376, Investigation of Immunotherapy-induced Alterations to Cellular Communication Networks in Pancreatic Ductal Adenocarcinoma (1F31CA284525-01A1). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/10898376. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*